Aquestive Therapeutics, Inc. AQST Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s interest expense?
- Aquestive Therapeutics, Inc. (AQST) reported interest expense of $2.9M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s interest expense changed year-over-year?
- Aquestive Therapeutics, Inc.'s interest expense increased by 4.3% year-over-year, from $2.78M to $2.9M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s interest expense?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s interest expense has grown at a 2.6% compound annual growth rate (CAGR), from $10.05M to $11.12M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.